1.
|
Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]
2022 |
Abstract |
|
2.
|
Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated gene [...]
2022 |
Abstract |
|
3.
|
Gene transcription is fundamental in establishing and maintaining cell identity and function. All normal cells are encoded with the same DNA, so transcription is essentia [...]
2024-02-23 |
Dissertation |
|
4.
|
November 2013 issue of the Scribe. Contents include clinical trials for acute myeloid leukemia treatment, care for senior patients, liability insurance, management of use [...]
2013-11 |
Other |
Medical Society of Metropolitan Portland records |
|
5.
|
This thesis is composed of two studies that utilizes different statistical methods to answer cancer research questions. The first study uses supervised and unsupervised s [...]
2023-09-13 |
Dissertation |
|
6.
|
Abnormal splicing events can promote drug resistance in a variety of cancer types, however, the full extent of genome-wide splicing in therapy-resistant AML is not fully [...]
2020 |
Abstract |
|
7.
|
Acute myeloid leukemia (AML) is the most common leukemia in adults and is primarily diagnosed in older patients. The combination of the BCL2 inhibitor, venetoclax, with a [...]
2024 |
Abstract |
|